Author:
Freeman Tracey L.,McElroy Anita K.
Reference79 articles.
1. Jenkin D, Wright D, Folegatti PM, Platt A, Poulton I, Lawrie A, Tran N, Boyd A, Turner C, Gitonga JN, Karanja HK, Mugo D, Ewer KJ, Bowden TA, Gilbert SC, Charleston B, Kaleebu P, Hill AVS, Warimwe GM (2023) Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. Lancet Infect Dis 23(8):956–964. https://doi.org/10.1016/S1473-3099(23)00068-3
2. Anywaine Z, Lule SA, Hansen C, Warimwe G, Elliott A (2022) Clinical manifestations of Rift Valley fever in humans: systematic review and meta-analysis. PLoS Negl Trop Dis 16(3):e0010233. https://doi.org/10.1371/journal.pntd.0010233. PMID: 35333856
3. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani AM, Al-Sayed MO, Abodahish AA, Khan AS, Ksiazek TG, Shobokshi O (2003) Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics.[see comment]. Clin Infect Dis 37(8):1084–1092. https://doi.org/10.1086/378747
4. El-Akkad AM (1978) Rift Valley fever outbreak in Egypt. October—December 1977. J Egypt Public Health Assoc 53(3–4):123–128
5. Fields BN, Knipe DM, Howley PM (2007) Fields’ virology, 5th edn. Wolters kluwer/Lippincott Williams & Wilkins, Philadelphia